The manufacturer of a breast cancer drug which has been deemed "too expensive" to be offered by the NHS has hit back at the decision.
Dr Jayson Dallas, general manager of Roche Products Limited, declared it "an incredible injustice."
Despite Roche offering a significant discount, we are once again disappointed that Nice has not shown any flexibility on access to Kadcyla.
Refusing patients access to this drug is an incredible injustice and tantamount to turning the clock back in cancer research and development. We plan to appeal this decision.
More top news
European court says US-EU treaty allowing transfer of personal data by US companies is invalid due to privacy fears.
Luxury car maker Lexus has made a full-size driveable 'Origami car' out of cardboard to celebrate the craftsmanship of their workers.
Who will get hired and who will get fired by Lord Sugar in this year's Apprentice?